Subject(s)
Acne Vulgaris , Dietary Supplements , Nonprescription Drugs , Humans , Cross-Sectional Studies , Acne Vulgaris/drug therapy , Acne Vulgaris/economics , United States/epidemiology , Dietary Supplements/economics , Adult , Nonprescription Drugs/economics , Nonprescription Drugs/administration & dosage , Female , Male , Young Adult , Administration, Topical , Middle Aged , Adolescent , Drug Prescriptions/statistics & numerical data , Drug Prescriptions/economics , Dermatologic Agents/economics , Dermatologic Agents/administration & dosage , Dermatologic Agents/therapeutic useSubject(s)
Acne Vulgaris , Adapalene , Benzoyl Peroxide , Clindamycin , Randomized Controlled Trials as Topic , Humans , Acne Vulgaris/drug therapy , Benzoyl Peroxide/therapeutic use , Benzoyl Peroxide/administration & dosage , Benzoyl Peroxide/adverse effects , Clindamycin/adverse effects , Clindamycin/therapeutic use , Clindamycin/administration & dosage , Clindamycin/analogs & derivatives , Adapalene/therapeutic use , Adapalene/administration & dosage , Treatment Outcome , Dermatologic Agents/adverse effects , Dermatologic Agents/therapeutic use , Dermatologic Agents/administration & dosage , Drug Combinations , Anti-Bacterial Agents/adverse effects , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic useABSTRACT
BACKGROUND: Polynucleotides stimulate collagen formation and are used clinically to enhance elasticity. In this study, we investigated current practices and perceived effectiveness of polynucleotide injection treatment for enlarged facial pores among cosmetic physicians. MATERIALS AND METHODS: A survey was developed to investigate clinicians' use and effectiveness of polynucleotides in the treatment of enlarged facial pores. This survey was distributed to clinicians at the Korean Aesthetic Surgery & Laser Society Autumn Symposium. RESULTS: A total of 407 physicians who used polynucleotides for enlarged facial pores were enrolled in the survey. Polynucleotides were used by 75.7%, 87.7%, and 72.2% of physicians for enlarged facial pores caused by excessive sebum production, reduced elasticity, and acne, respectively. Among those users, 81.4%, 83.8%, and 76.8% in those same categories, respectively, responded that polynucleotides were "very effective" or "effective." Furthermore, most clinicians combined polynucleotides with microneedle radiofrequency as energy-based devices and with botulinum toxin as injection therapy. CONCLUSION: This study highlights the widespread use and perceived efficacy of polynucleotide injection among cosmetic physicians in the Republic of Korea for enlarged facial pores due to excessive sebum production, reduced elasticity, and acne. Positive feedback from practitioners supports the benefits of using polynucleotides in enlarged facial pore treatment.
Subject(s)
Cosmetic Techniques , Polynucleotides , Practice Patterns, Physicians' , Humans , Practice Patterns, Physicians'/statistics & numerical data , Polynucleotides/administration & dosage , Face/pathology , Female , Surveys and Questionnaires , Republic of Korea , Skin Aging/drug effects , Male , Adult , Dermal Fillers/administration & dosage , Middle Aged , Acne Vulgaris/drug therapy , Acne Vulgaris/pathologyABSTRACT
Background: The occurrence of acne in patients treated with Janus kinase (JAK) inhibitors for skin diseases is a potential issue, which may reduce treatment adherence.Purpose: To systematically analyzes randomized clinical trials (RCTs) of JAK inhibitors in dermatological indications for the risk of acne as an adverse event.Methods: A meta-analysis of odds ratios (ORs) for acne incidence was conducted. Data were quantitatively synthesized using random-effects meta-analysis. Surface under the cumulative ranking curve (SUCRA) values representing the relative ranking probabilities of treatments were obtained. Analyses were performed using R statistical software version 4.4.0.Results: A total of 11,396 patients were included from 24 studies. The incidence of acne for JAK inhibitors was ranked according to the SUCRA as follows: JAK1 inhibitors > TYK2 inhibitors > combined JAK1 and JAK2 inhibitors > combined JAK1 and TYK2 inhibitors > JAK3 + TEC inhibitors > pan-JAK inhibitors. ORs were higher for longer durations of drug use and larger dosages. Subgroup analyses by disease indication revealed increased ORs for psoriasis (5.52 [95% CI, 1.39-21.88]), vitiligo (4.15 [95% CI, 1.27-13.58]), alopecia areata (3.86 [95% CI, 1.58-9.42]), and atopic dermatitis (2.82 [95% CI, 1.75-4.54]). The use of JAK inhibitors in patients with systemic lupus erythematosus (SLE) may not significantly increase the incidence of acne.Conclusions: There are higher rates of acne following treatment with JAK inhibitors for dermatologic indications, particularly with longer durations and larger dosages. Pan-JAK inhibitors exhibit the lowest incidence of acne.
Subject(s)
Acne Vulgaris , Janus Kinase Inhibitors , Humans , Acne Vulgaris/drug therapy , Incidence , Janus Kinase Inhibitors/adverse effects , Network Meta-Analysis , Psoriasis/drug therapy , Randomized Controlled Trials as Topic , Skin Diseases/drug therapy , Skin Diseases/chemically inducedABSTRACT
BACKGROUND: Acne vulgaris is a multifactorial dermatosis primary of the face and trunk. Erythema, pruritus, and xerosis are frequent adverse effects of first-line acne treatment and, if not appropriately counseled and managed, can exacerbate, leading to regimen nonadherence and poor outcomes. METHODS: A panel of 6 dermatologists (five from the Nordic European Countries and one from the UK) employed a modified Delphi method and reached a consensus on a practical acne treatment and maintenance algorithm integrating skincare based on the best available evidence, and the panels' clinical experience, and opinions. RESULTS: The Nordic European Countries Acne Skincare Algorithm (NECASA) recommends integrating skincare and nonprescription acne treatment into acne regimens, addressing the relative lack of standardized guidance on their use as mono or adjunctives to acne treatment. The algorithm uses stratification by acne subtype and discusses management approaches per type of acne (comedonal, papulopustular, and nodulocystic acne), severity (mild to moderate and severe), and maintenance treatment. Skincare monotherapy may reduce acne lesions and maintain clearance in patients with mild acne. Adjunctive skincare may enhance the efficacy and improve tolerability of acne treatment, reduce pigmentary alterations, and improve skin barrier function. CONCLUSIONS: The NECASA algorithm may serve as a roadmap for integrating skincare in managing acne patients and tailoring acne treatment to improve adherence and tolerance to treatment and patient outcomes. J Drugs Dermatol. 2024;23(9):782-788. doi:10.36849/JDD.8472.
Subject(s)
Acne Vulgaris , Algorithms , Dermatologic Agents , Skin Care , Acne Vulgaris/therapy , Acne Vulgaris/drug therapy , Acne Vulgaris/diagnosis , Humans , Dermatologic Agents/administration & dosage , Dermatologic Agents/therapeutic use , Skin Care/methods , Scandinavian and Nordic Countries , Delphi Technique , Severity of Illness Index , Practice Guidelines as TopicABSTRACT
BACKGROUND: Mild-to-moderate acne vulgaris (AV) is common among adults, and benzoyl peroxide (BPO) has a long history of efficacy in reducing AV lesions. The efficacy of BPO is comparable for concentrations from 2.5% to 10% used as leave-on therapy, but tolerability is usually best at lower concentrations formulated in well-designed vehicles and with newer formulation methods such as micronization. This study assessed the efficacy and safety of a 2.6% BPO cleanser (Complexion Clearing AV Cleanser, CCAC) in mild-to-moderate AV. METHODS: This was a single-center, open-label, 4-week study of subjects aged 18 to 45 years (n=28) with self-perceived sensitive skin and mild-to-moderate AV. CCAC was applied twice daily (morning and evening) on damp skin. Assessments included lesion counts, clinical photography with porphyrin analysis, patient self-assessment questionnaires, collection of adverse events, and standard tolerability ratings. RESULTS: Total lesion counts were significantly reduced by week 1 of CCAC cleanser use (-25.2%, P<0.05). At week 4, AV lesions were numerically reduced but did not reach statistical significance. Additionally, there was a significant reduction of porphyrin counts at week 1 (-19.4% right side face, -28.8% left side, P<0.05 vs baseline). CCAC was well tolerated, with no significant increase in tolerability ratings at any time point compared to baseline, and patients reported good satisfaction. CONCLUSIONS: CCAC was efficacious in reducing AV lesions in as little as one week, and a trend in reduction was shown through week 4. Additionally, this 2.6% BPO cleanser was also shown to be very well tolerated and well-liked by subjects with self-perceived sensitive skin. J Drugs Dermatol. 2024;23(9):764-768. doi:10.36849/JDD.8219.
Subject(s)
Acne Vulgaris , Benzoyl Peroxide , Humans , Adult , Female , Male , Benzoyl Peroxide/administration & dosage , Benzoyl Peroxide/adverse effects , Young Adult , Acne Vulgaris/drug therapy , Adolescent , Middle Aged , Treatment Outcome , Dermatologic Agents/administration & dosage , Dermatologic Agents/adverse effects , Administration, CutaneousABSTRACT
The optimal frequency and timing of laboratory monitoring during isotretinoin treatment remains controversial. We aimed to investigate the frequency, timing, and severity of abnormal results during isotretinoin for acne. We conducted a retrospective cohort study comprising 444 acne patients prescribed isotretinoin at Boston Medical Center from 2004 to 2017; these patients had at least one available baseline laboratory result. We categorized patients into two groups: group A (normal values at baseline and during the first 2 months of isotretinoin therapy) and group B (abnormal values at baseline or during the first 2 months of isotretinoin therapy) and assessed the laboratory values after 2 months. The frequency of abnormal results for triglycerides, cholesterol, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) after 2 months for patients in group A was 21.1%, 13.6%, 8.8%, and 6.0%, respectively, with very rare grade 2 (moderate) or higher abnormalities. In contrast, the frequency of abnormal results for patients in group B for triglycerides, cholesterol, AST, and ALT was higher at 67.9%, 88.0%, 40.0%, and 25.0%, respectively (P < 0.05, except for ALT). No patient developed higher than grade 1 (mild) complete blood count (CBC) abnormality. This study proposed that healthy patients with normal results at baseline and during the first 2 months of isotretinoin therapy might not need routine monitoring after month 2 of medication. Routine monitoring of CBC is not necessary.
Subject(s)
Acne Vulgaris , Alanine Transaminase , Aspartate Aminotransferases , Dermatologic Agents , Isotretinoin , Humans , Isotretinoin/therapeutic use , Isotretinoin/adverse effects , Isotretinoin/administration & dosage , Acne Vulgaris/drug therapy , Retrospective Studies , Male , Dermatologic Agents/therapeutic use , Dermatologic Agents/administration & dosage , Dermatologic Agents/adverse effects , Female , Alanine Transaminase/blood , Young Adult , Aspartate Aminotransferases/blood , Adolescent , Adult , Triglycerides/blood , Cholesterol/blood , Time Factors , Drug Monitoring/methodsABSTRACT
Acne vulgaris is a common dermatological diagnosis observed in pediatric patients with skin of color, often resulting in scarring, keloid formation, and post-inflammatory hyperpigmentation, significantly impacting their quality of life. This exploratory retrospective chart review included 77 black pediatric patients seen at a tertiary care center for acne vulgaris between 2018 and 2023. We analyzed demographics, acne descriptors, and treatment modalities. The most common acne morphology was comedonal acne (83.6%), with 71% of the patients being female. Significant age differences were observed particularly for acne at the chin and overall face. Treatment regimens commonly prescribed included combinations of adapalene and benzoyl peroxide (22%), topical antibiotics, tretinoin, and benzoyl peroxide (34%). Given the higher risk of sequelae for patients with darker skin, it is crucial to address their unique treatment needs. This study highlights the distinctive characteristics of acne in black pediatric patients and calls for further research to enhance our understanding and treatment of this population. Limitations include the lack of direct patient interactions and reliance on chart data. Further studies are needed to compare acne presentation in skin of color of other populations, refining our knowledge of acne clinical presentation, complications, and treatment modalities for diverse patient populations.
Subject(s)
Acne Vulgaris , Anti-Bacterial Agents , Black or African American , Dermatologic Agents , Humans , Acne Vulgaris/drug therapy , Female , Child , Male , Retrospective Studies , Adolescent , Dermatologic Agents/therapeutic use , Anti-Bacterial Agents/therapeutic use , Benzoyl Peroxide/therapeutic use , Tretinoin/therapeutic use , Age FactorsABSTRACT
Acne caused by inflammation of hair follicles and sebaceous glands is a common chronic skin disease. Arctigenin (ATG) is an extract of Arctium lappa L., which has significant anti-inflammatory effects. However, the effect and mechanism of ATG in cutaneous inflammation mediated by Cutibacterium acnes (C. acnes) has not been fully evaluated. The purpose of this study was to explore the effect and potential mechanism of ATG in the treatment of acne through network pharmacology and experimental confirmation. An acne model was established by injected live C. acnes into living mice and treated with ATG. Our data showed that ATG effectively improved acne induced by live C. acnes, which was confirmed by determining ear swelling rate, estradiol concentration and hematoxylin and eosin (H&E) staining. In addition, ATG inhibited the NLRP3 inflammasome signaling pathway in mice ear tissues and reduced the secretion of pro-inflammatory cytokines IL-1ß to relieve inflammation. The results of network pharmacology and molecular docking confirmed that ATG can regulate 17ß-Estradiol (E2) levels through targeted to CYP19A1, and finally inhibited skin inflammation. Taken together, our results confirmed that ATG regulated E2 secretion by targeting CYP19A1, thereby inhibiting the NLRP3 inflammasome signaling pathway and improving inflammation levels in acne mice. This study provides a basis for the feasibility of ATG in treating acne in clinical practice.
Subject(s)
Acne Vulgaris , Aromatase , Furans , Lignans , Molecular Docking Simulation , Network Pharmacology , Animals , Furans/chemistry , Furans/pharmacology , Mice , Lignans/pharmacology , Lignans/chemistry , Lignans/therapeutic use , Acne Vulgaris/drug therapy , Acne Vulgaris/microbiology , Aromatase/metabolism , Aromatase/chemistry , Signal Transduction/drug effects , Skin/pathology , Skin/drug effects , Skin/metabolism , Inflammation/drug therapy , Inflammation/metabolism , NLR Family, Pyrin Domain-Containing 3 Protein/metabolism , NLR Family, Pyrin Domain-Containing 3 Protein/antagonists & inhibitors , Inflammasomes/metabolism , Humans , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/chemistry , Anti-Inflammatory Agents/therapeutic use , Propionibacterium acnes/drug effects , Interleukin-1beta/metabolism , Disease Models, AnimalABSTRACT
BACKGROUND: Acne vulgaris is a complex, multifactorial, inflammatory skin condition. Although frequently presented at dermatology clinics, the literature on adult acne is scarce, particularly concerning skin barrier function and management. We aimed to provide insights into the role of skin barrier integrity in adult acne patients and the role of cleansers and moisturizers as adjunctive to treating and maintaining adult acne. Methods: A panel of eight dermatologists who treat adult patients with acne developed a consensus paper on the role of skin barrier function and skin care in adult acne management. The modified Delphi method comprised a face-to-face meeting and online follow-up to discuss the results of a scoping literature review. Drawing from their experience and opinions, they agreed on seven consensus statements. Results: Epidermal barrier dysfunction plays a vital role in acne pathogenesis and asymmetrically impacts adult female acne. Erythema, pruritus, peeling, and xerosis are common adverse effects of first-line acne treatment options and, if not appropriately counseled and managed, can exacerbate, leading to regimen nonadherence and poor patient experience and outcomes. CONCLUSION: Improving patient knowledge of comprehensive acne treatments, including quality adjunctive cleansers and moisturizers, may maximize regimen efficacy and provide patients with personalized and successful acne treatment and maintenance tools. J Drugs Dermatol. 2024;23(8):674-679. doi:10.36849/JDD.8471.
Subject(s)
Acne Vulgaris , Skin Care , Humans , Acne Vulgaris/therapy , Acne Vulgaris/drug therapy , Skin Care/methods , Adult , Dermatologic Agents/administration & dosage , Dermatologic Agents/therapeutic use , Female , Delphi Technique , ConsensusSubject(s)
Acne Vulgaris , Dermatologic Agents , Isotretinoin , Practice Patterns, Physicians' , Humans , Isotretinoin/therapeutic use , Isotretinoin/adverse effects , Isotretinoin/administration & dosage , Cross-Sectional Studies , Practice Patterns, Physicians'/statistics & numerical data , Dermatologic Agents/administration & dosage , Dermatologic Agents/therapeutic use , Female , Male , Acne Vulgaris/drug therapy , Adult , Drug Prescriptions/statistics & numerical data , Adolescent , Middle AgedABSTRACT
Isotretinoin is widely used for treatment of severe cystic acne; however, its use is accompanied by mucocutaneous adverse effects. The established protocol for conducting cutaneous procedures on patients undergoing current or recent treatment with isotretinoin recommends a cessation period of at least 6 months to mitigate risks for delayed wound healing and hypertrophic scarring due to medication-induced skin fragility. We present a unique case of isotretinoin-induced skin fragility resulting in blistering and erosions on the palms of a 25-year-old competitive aerial trapeze artist. This case highlights the underrecognized risk for skin vulnerability in athletes undergoing isotretinoin treatment and the importance of guiding athletes on heightened skin vulnerability during isotretinoin treatment.
Subject(s)
Dermatologic Agents , Isotretinoin , Humans , Isotretinoin/adverse effects , Isotretinoin/administration & dosage , Dermatologic Agents/adverse effects , Dermatologic Agents/administration & dosage , Adult , Male , Acne Vulgaris/drug therapy , AthletesSubject(s)
Isotretinoin , Pharmacists , Humans , Pregnancy , Female , Ireland , Pharmacists/organization & administration , Isotretinoin/therapeutic use , Dermatologic Agents/therapeutic use , Dermatologic Agents/administration & dosage , Drug Prescriptions/statistics & numerical data , Professional Role , Acne Vulgaris/drug therapy , Pregnancy Complications/prevention & control , Pregnancy Complications/drug therapyABSTRACT
Acne is one of the most common dermatological conditions, peaking during adolescence and early adulthood, affecting about 85% of individuals aged 12-24. Although often associated with teenage years, acne can occur at any age, impacting over 25% of women and 12% of men in their forties. Treatment strategies vary depending on the severity, including the use of topical gels or creams containing benzoyl peroxide and retinoids, antibiotics, and systemic or topical isotretinoin. However, these treatments can cause irritation, allergies, and other toxic side effects. Currently, there is no natural-based alternative for antibacterial photodynamic therapy targeting acne using marine drugs or extracts. Through a bioguided screening approach, we identified the ethanol extract of Skeletonema marinoi as highly phototoxic against three bacterial species associated with acne-Cutibacterium acnes, Staphylococcus aureus, and Staphylococcus epidermidis. This extract exhibited phototoxicity in planktonic bacteria under white and red light, disrupted bacterial biofilms, reduced sebum production but also showed phototoxicity in keratinocytes, highlighting the importance of the specific targeting of treatment areas. Further investigations, including fractionation and high-resolution structural analysis, linked the observed phototoxicity to a high concentration of pheophorbide a in the extract. Given its notable in vitro efficacy, this extract holds promising potential for clinical evaluation to manage mild acne. This discovery paves the way for further exploration of Skeletonema pigment extracts, extending their potential applications beyond acne phototherapy to include dermocosmetics, veterinary medicine, and other phototherapy uses.
Subject(s)
Acne Vulgaris , Staphylococcus epidermidis , Acne Vulgaris/drug therapy , Acne Vulgaris/microbiology , Humans , Staphylococcus epidermidis/drug effects , Anti-Bacterial Agents/pharmacology , Staphylococcus aureus/drug effects , Biofilms/drug effects , Ethanol/chemistry , Propionibacteriaceae/drug effects , Photochemotherapy/methods , Phaeophyceae/chemistry , Keratinocytes/drug effects , Microbial Sensitivity Tests , FemaleABSTRACT
Vitamin A derivatives have inhibitory effects on cartilage tissue, such as decreasing chondrocyte proliferation and collagen synthesis, and increasing the loss of glycosaminoglycans and proteoglycans. Therefore, isotretinoin (a vitamin A derivative) may play a role in the pathogenesis of cartilage-related diseases like osteoarthritis by affecting the balance of cartilage tissue. The aim of this study was to evaluate the distal femoral cartilage thickness in acne patients under the systemic isotretinoin therapy and to determine whether it constitutes a risk factor for the development of osteoarthritis. The study included 52 patients (42 female, 10 male, mean age 23.31 ± 3.89 years) who were prescribed systemic isotretinoin for acne and completed at least 3 months of treatment, along with 45 healthy controls ((35 female, 10 male, mean age 23.85 ± 4.77 years). Bilateral distal femoral cartilage thickness was measured by ultrasonography before isotretinoin treatment and after the completion of the third month of treatment. After treatment, a statistically significant increase was found in the thickness of the right medial, right lateral, left medial, left lateral, and left intercondylar cartilage (p = 0.014, 0.012, 0.019, 0.027, 0.002, respectively). There was also an increase in the right intercondylar cartilage thickness, but this was not statistically significant (p = 0.1). Systemic isotretinoin seems to make cartilage thicker. The increase in femoral cartilage thickness observed after short-term isotretinoin treatment might be an indicator of very early-stage osteoarthritis. Extended follow-up studies with larger participant pools are necessary to substantiate this result.
Subject(s)
Acne Vulgaris , Cartilage, Articular , Femur , Isotretinoin , Humans , Isotretinoin/adverse effects , Isotretinoin/therapeutic use , Isotretinoin/administration & dosage , Female , Male , Acne Vulgaris/drug therapy , Acne Vulgaris/pathology , Acne Vulgaris/diagnosis , Adult , Young Adult , Cartilage, Articular/pathology , Cartilage, Articular/drug effects , Cartilage, Articular/diagnostic imaging , Femur/diagnostic imaging , Femur/drug effects , Femur/pathology , Ultrasonography , Dermatologic Agents/adverse effects , Dermatologic Agents/therapeutic use , Dermatologic Agents/administration & dosage , Osteoarthritis/drug therapy , Osteoarthritis/pathology , Osteoarthritis/diagnostic imaging , Risk Factors , Case-Control StudiesABSTRACT
Acne is a chronic inflammatory skin disease with wide-ranging effects, involving factors such as Propionibacterium acnes (P. acnes) infection and sebum hypersecretion. Current acne treatments are challenged by drug resistance. 5-aminolaevulinic acid (ALA) -based photodynamic therapy (PDT) has been widely used in the clinical treatment of acne, however, the mechanism of its action remains to be elucidated. In this study, by constructing a mice ears model of P. acnes infection, we found that ALA-PDT inhibited the proliferation of P. acnes in vivo and in vitro, significantly ameliorated ear swelling, and blocked the chronic inflammatory process. In vitro, ALA-PDT inhibited lipid secretion and regulated the expression of lipid synthesis and metabolism-related genes in SZ95 cells. Further, we found that ALA-PDT led to DNA damage and apoptosis in SZ95 cells by inducing mitochondrial stress and oxidative stress. Altogether, our study demonstrated the great advantages of ALA-PDT for the treatment of acne and revealed that the mechanism may be related to the blockade of chronic inflammation and the suppression of lipid secretion by ALA-PDT.
Subject(s)
Acne Vulgaris , Aminolevulinic Acid , Mitochondria , Oxidative Stress , Photochemotherapy , Propionibacterium acnes , Animals , Aminolevulinic Acid/pharmacology , Aminolevulinic Acid/therapeutic use , Acne Vulgaris/drug therapy , Photochemotherapy/methods , Oxidative Stress/drug effects , Propionibacterium acnes/drug effects , Mice , Mitochondria/drug effects , Mitochondria/metabolism , Photosensitizing Agents/pharmacology , Photosensitizing Agents/therapeutic use , Cell Line , Sebaceous Glands/drug effects , Sebaceous Glands/pathology , Sebaceous Glands/metabolism , Humans , Disease Models, Animal , Lipid Metabolism/drug effects , Apoptosis/drug effects , Ear/pathologyABSTRACT
Acne vulgaris is a complex condition involving factors that affect the pilosebaceous unit. A primary manifestation of acne pathology is the development of comedones, often linked to the overproduction of sebum resulting from 5α-dihydrotestosterone (5α-DHT) and insulin activity. Ozenoxacin is a topical quinolone that exhibits potent antibacterial activity against Cutibacterium acnes (C. acnes). It is commonly used to treat acne associated with this bacterium; however, its effect on sebum production within the sebaceous glands remains unclear. In this study, the effects of ozenoxacin on sebum production were examined using insulin- and 5α-DHT-differentiated hamster sebocytes. Ozenoxacin showed a dose-dependent inhibition of lipid droplet formation and triacylglycerol (TG) production, which is a major component of sebum. In addition, it suppressed the expression of diacylglycerol acyltransferase 1, stearoyl-CoA desaturase-1, and perilipin-1 mRNA, all important factors involved in sebum synthesis, in a dose-dependent manner. Moreover, ozenoxacin decreased phosphorylated 40S ribosomal protein S6 levels downstream of the mechanistic/mammalian target of rapamycin complex 1 (mTORC1), without altering the phosphorylation of Akt, an upstream regulator of mTORC1, in both insulin- and 5α-DHT-treated hamster sebocytes. Interestingly, nadifloxacin, but not clindamycin, exhibited a similar suppression of sebum production, albeit with lesser potency compared with ozenoxacin. Furthermore, a topical application of a 2% ozenoxacin-containing lotion to the auricle skin of hamsters did not affect the size of the sebaceous glands or epidermal thickness. Notably, it decreased the amount of TG on the skin surface. The results provide novel insights into the sebum-inhibitory properties of ozenoxacin, indicating its potential efficacy in controlling microbial growth and regulating sebum production for acne management.
Subject(s)
Acne Vulgaris , Mechanistic Target of Rapamycin Complex 1 , Quinolones , Sebaceous Glands , Sebum , Triglycerides , Animals , Sebum/metabolism , Sebum/drug effects , Sebaceous Glands/drug effects , Sebaceous Glands/pathology , Sebaceous Glands/metabolism , Sebaceous Glands/cytology , Mechanistic Target of Rapamycin Complex 1/metabolism , Mechanistic Target of Rapamycin Complex 1/antagonists & inhibitors , Quinolones/pharmacology , Triglycerides/metabolism , Acne Vulgaris/drug therapy , Acne Vulgaris/pathology , Aminopyridines/pharmacology , Diacylglycerol O-Acyltransferase/metabolism , Diacylglycerol O-Acyltransferase/antagonists & inhibitors , Cricetinae , Anti-Bacterial Agents/pharmacology , Perilipin-1/metabolism , Stearoyl-CoA Desaturase/metabolism , Stearoyl-CoA Desaturase/antagonists & inhibitors , Lipid Droplets/drug effects , Lipid Droplets/metabolism , Cell Differentiation/drug effects , Cells, Cultured , Insulin/metabolism , MesocricetusABSTRACT
Acne is one of the most common skin conditions worldwide, with multifactorial origins it affects areas of the skin with hair follicles and sebaceous glands that become clogged. Bacterial incidence aggravates treatment due to resistance to antimicrobial agents and production of virulence factors such as biofilm formation. Based on these information, this study aims to conduct in vitro evaluations of the antibacterial activity of essential oils (EOs), alone and in combination, against Propionibacterium acnes, Staphylococcus aureus, and Staphylococcus epidermidis in planktonic and biofilm forms. This study also assessed the anti-inflammatory potential (TNF-α) and the effects of EOs on the viability of human keratinocytes (HaCaT), murine fibroblasts (3T3-L1), and bone marrow-derived macrophages (BMDMs). Of all EOs tested, 13 had active action against P. acnes, 9 against S. aureus, and 9 against S. epidermidis at concentrations of 0.125-2.0 mg/mL. Among the most active plant species, a blend of essential oil (BEOs) was selected, with Cymbopogon martini (Roxb.) Will. Watson, Eugenia uniflora L., and Varronia curassavica Jacq., the latter due to its anti-inflammatory action. This BEOs showed higher inhibition rates when compared to chloramphenicol against S. aureus and S. epidermidis, and higher eradication rates when compared to chloramphenicol for the three target species. The BEOs did not affect the cell viability of cell lines evaluated, and the levels of TNF-α decreased. According to these results, the BEOs evaluated showed potential for the development of an alternative natural formulation for the treatment of acne.